Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYCCP's Cash to Debt is ranked higher than
85% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. CYCCP: No Debt )
CYCCP' s 10-Year Cash to Debt Range
Min: 1.16   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CYCCP's Interest Coverage is ranked higher than
69% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCCP: No Debt )
CYCCP' s 10-Year Interest Coverage Range
Min: -1000   Max: 1000
Current: No Debt

-1000
1000
F-Score: 1
Z-Score: -19.62
M-Score: -46.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3156.26
CYCCP's Operating margin (%) is ranked higher than
52% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. CYCCP: -3156.26 )
CYCCP' s 10-Year Operating margin (%) Range
Min: -115336.4   Max: 19636.4
Current: -3156.26

-115336.4
19636.4
Net-margin (%) -3306.17
CYCCP's Net-margin (%) is ranked higher than
54% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. CYCCP: -3306.17 )
CYCCP' s 10-Year Net-margin (%) Range
Min: -152366.7   Max: -463.3
Current: -3306.17

-152366.7
-463.3
ROE (%) -74.63
CYCCP's ROE (%) is ranked higher than
65% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. CYCCP: -74.63 )
CYCCP' s 10-Year ROE (%) Range
Min: -373.6   Max: -19.6
Current: -74.63

-373.6
-19.6
ROA (%) -57.86
CYCCP's ROA (%) is ranked higher than
67% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. CYCCP: -57.86 )
CYCCP' s 10-Year ROA (%) Range
Min: -169.6   Max: -16.8
Current: -57.86

-169.6
-16.8
Revenue Growth (%) -24.00
CYCCP's Revenue Growth (%) is ranked higher than
96% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. CYCCP: -24.00 )
CYCCP' s 10-Year Revenue Growth (%) Range
Min: -53.3   Max: 27
Current: -24

-53.3
27
EBITDA Growth (%) -36.50
CYCCP's EBITDA Growth (%) is ranked higher than
57% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. CYCCP: -36.50 )
CYCCP' s 10-Year EBITDA Growth (%) Range
Min: -45.1   Max: 8.3
Current: -36.5

-45.1
8.3
» CYCCP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CYCCP



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP9.316.446% Convertible Exchangeable Preferred Stock

Ratios

vs
industry
vs
history
EV-to-EBIT 0.20
CYCCP's EV-to-EBIT is ranked higher than
97% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. CYCCP: 0.20 )
CYCCP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.2

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 6.44
CYCCP's Dividend Yield is ranked lower than
349% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. CYCCP: 6.44 )
CYCCP' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 6.44

Yield on cost (5-Year) 6.60
CYCCP's Yield on cost (5-Year) is ranked lower than
338% of the 169 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. CYCCP: 6.60 )
CYCCP' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 6.6

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UXI2.Germany
Cyclacel Pharmaceuticals, Inc., was founded in 1996, and is incorporated Delaware. The Company is a development-stage biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Cyclacel's clinical development priorities are focused on sapacitabine: Acute myeloid leukemia, Myelodysplastic syndromes, and Non-small cell lung cancer.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide